Lindner Jonathan R
Division of Cardiovascular Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road Portland, OR 97239, USA.
Cardiovasc Res. 2009 Nov 1;84(2):182-9. doi: 10.1093/cvr/cvp302. Epub 2009 Sep 26.
The cellular immune response plays an important role in almost every major form of cardiovascular disease. The ability to image the key aspects of the immune response in the clinical setting could be used to improve diagnostic information, to provide important prognostic or risk information, and to customize therapy according to disease phenotype. Accordingly, targeted imaging probes for assessing inflammation have been developed for essentially all forms of medical imaging. Molecular imaging of inflammation with contrast ultrasound relies on the detection of targeted microbubble or other gas-filled particle contrast agents. These agents are confined to the vascular space and, hence, have been targeted to either activated leucocytes or endothelial cell adhesion molecules that are upregulated in inflammation and mediate leucocyte recruitment and adhesion. This review focuses on the inflammation-targeting strategies for ultrasound contrast agents and how they have been matched to cardiovascular disease states such as myocardial ischaemia, infarction, atherosclerosis, transplant rejection, and arteriogenesis.
细胞免疫反应在几乎每种主要形式的心血管疾病中都起着重要作用。在临床环境中对免疫反应的关键方面进行成像的能力可用于改善诊断信息、提供重要的预后或风险信息,以及根据疾病表型定制治疗方案。因此,针对几乎所有形式的医学成像,都已开发出用于评估炎症的靶向成像探针。利用超声造影进行炎症的分子成像依赖于对靶向微泡或其他充气颗粒造影剂的检测。这些造影剂局限于血管腔内,因此已被靶向到炎症中上调的活化白细胞或内皮细胞粘附分子,它们介导白细胞的募集和粘附。本综述重点关注超声造影剂的炎症靶向策略,以及它们如何与心血管疾病状态(如心肌缺血、梗死、动脉粥样硬化、移植排斥和动脉生成)相匹配。